



## **Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference**

January 3, 2022

FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced that the Company's management team will present at the following investor conferences in January:

### **40th Annual J.P. Morgan Health Care Conference**

- Date: January 13, 2022
- Time: 11:15 a.m. ET

### **H.C. Wainwright BioConnect 2022 Virtual Conference**

- Date: January 10, 2022
- Time: 7:00 a.m. ET

A live audio webcast of each presentation will be available on the investor relations page of Terns' website at <http://ir.ternspharma.com>. A replay of the webcast will be archived on Terns' website for 30 days following the presentation.

### **About Terns Pharmaceuticals**

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis, or NASH. Terns' pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR- $\beta$  agonist, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: [www.ternspharma.com](http://www.ternspharma.com).

### **Contacts for Terns**

#### **Investors**

Justin Ng

[investors@ternspharma.com](mailto:investors@ternspharma.com)

#### **Media**

Jenna Urban

Berry & Company Public Relations

[media@ternspharma.com](mailto:media@ternspharma.com)